Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

PET Research At University Of Zurich Is Sponsorsed By MEDRAD

MEDRAD, Inc has signed a research agreement with the University of Zurich to study dynamic PET imaging with the MEDRAD Intego PET Infusion System. The researchers will utilize MEDRAD’s latest technology to more precisely control the radioactive dose delivered during PET imaging procedures. Specifically, the study will examine patients with tumors in the abdomen or chest and compare standard quantitative techniques, such as standard uptake value (SUV), with more advanced kinetic and compartmental models. One of the primary goals of the research is to explore how controlled delivery technology can enable dynamic imaging by providing additional clinical utility and making these advanced techniques more practical. The Intego System is a key element in the research by enabling the benefit of repeatable infusion of the prescribed FDG dose to all subjects in the study. “The research will explore the clinical viability of dynamic imaging with PET,” said Dr. Alfred Buck, University of Zurich (Switzerland). The Intego System automatically extracts a patient dose from a multi-dose vial and delivers it directly to the patient, virtually eliminating manual dose preparation and handling, and the corresponding radiation exposure to the technologist inherent in manual preparation. With the Intego System’s dose-on-demand capability, the prescribed dose can be delivered when the patient and clinician are ready. This enables the clinician to efficiently and easily respond to schedule changes, patient delays, and add-on patients. Innovative features, including real-time dose availability information, an integrated ionization chamber, and an optional weight-based dose calculation, allow the healthcare provider to more precisely customize each patient’s dose. Safety features include a tungsten multi-dose vial shield, a fully lead-lined mobile cart, and an automated saline flush to remove residual FDG from the line after each infusion. “Supporting this research with the University of Zurich is an exciting opportunity for us. We believe the Intego System can be a very important tool for advancing PET imaging in the clinical setting, leading to better patient management and clinical outcomes,” said Doug Descalzi, Executive Director, MEDRAD Molecular Imaging.